Shire (NSDQ:SHPGY) said it agreed to acquire Pervasis Therapeutics and its endothelial cell technology for an undisclosed amount.
Insulet
Device tax spurs Hill-Rom to lay off 200 | Wall Street Beat
Hill-Rom Holdings (NYSE:HRC) said it will lay off about 3% of its workforce, or roughly 200 workers, as it maneuvers to confront the medical device tax set to go into effect next year.
MassDevice.com +7 | The top 7 med-tech stories for the week of February 13, 2012.
Say hello to MassDevice +7, a bite-sized view of the top seven med-tech stories of the week. This latest feature of MassDevice.com’s coverage highlights our seven biggest and most influential stories from the week’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry.
If you read nothing else this weekend, make sure you’re still in the know with MassDevice +7.
Diabetes: Insulet inks deal with J&J’s LifesScan for next-gen OmniPod
Ortho market growth stable but low | Wall Street Beat
The market for hip and knee implants is stable but mired in a low-growth stage, according to analysts who attended the American Academy of Orthopedic Surgeons conference in San Francisco last week.
Although the abrupt departure of Stryker CEO Steve MacMillan drew the lion’s share of attention at the AAOS event, analysts from Barclays Capital and Leerink Swann agreed that the sector’s outlook calls for low-single-digit growth.
Moody’s raises Boston Scientific rating again | Wall Street Beat
Insulet gains after paring Q4, 2011 losses | Earnings Roundup
Wall Street investors drove Insulet (NSDQ:PODD) shares up nearly 4% today ahead of the insulin management company’s 4th-quarter and full-year earnings statement.
Bedford, Mass.-based Insulet posted losses of $14.3 million, or 30 cents per share, on sales of $47.2 million for the 3 months ended Dec. 31, 2011, adding 70% to the top line and shaving 31.3 percent off of its losses, compared with the same period in 2010.
Insulet gains after paring Q4, 2011 losses
Wall Street investors drove Insulet (NSDQ:PODD) shares up nearly 4% today ahead of the insulin management company’s 4th-quarter and full-year earnings statement.
Bedford, Mass.-based Insulet posted losses of $14.3 million, or 30 cents per share, on sales of $47.2 million for the 3 months ended Dec. 31, 2011, adding 70% to the top line and shaving 31.3 percent off of its losses, compared with the same period in 2010.
Electromed: Q2, H2 2012 sales, earnings growth to slow | Wall Street Beat
Electromed (NSDQ:ELMD) CEO Robert Hansen said the company expects its sales and earnings numbers to slide for the 2nd quarter and 2nd half of 2012, after a sales force restructuring hit its top line.
FDA clears Abbott’s Freestyle for use with Insulet’s OmniPod
Olympus shares rise on abated de-listing threat | MassDevice.com Wall Street Beat
Shares of Olympus Corp. (TYO:7733) regained more than 17 percent over the weekend after the Tokyo stock exchange indicated it might not de-list the world’s largest endoscope maker, brought low by a scheme to hide its losses with buyouts.